Home >> Tag Archives: Diaceutics—

Tag Archives: Diaceutics—

IGHV clinical utility in CLL and preferred testing practices

Webinar presenter Curtis A. Hanson, MD, Professor of Laboratory Medicine and Pathology Mayo Clinic College of Medicine, Rochester, Minnesota, reviews the role of key High Risk (HR) biomarkers in CLL, focusing on clinical evidence and raising awareness for IGHV mutation status as an important CLL biomarker that can help guide treatment decisions. He also provides best practices for how and when to request IGHV testing and how to perform testing for IGHV mutation status in CLL patients. This on-demand webinar originally broadcast on February 28, 2019.

Read More »

Diaceutics teams up with Lenovo and Intel

March 9, 2018—Diaceutics, based in Dundalk, Ireland, will collaborate with tech companies Lenovo and Intel to leverage their vast proprietary database of patient testing data. Diaceutics will use artificial intelligence to see whether patients can be grouped according to diagnostic test information in hopes the data can help identify ways to improve diagnosis, treatment, and outcomes for patients with similar ...

Read More »